Description of original award (Fiscal Year 2021, $290,353)
The ever-changing climate of cannabis
decriminalization and/or legalization has significantly impacted forensic laboratories and is anticipated to increase the caseload in forensic toxicology. In addition, products claiming to contain other cannabinoids, including cannabidiol and tetrahydrocannabinolic acid, have become widely available.
The goal of this research project is to develop and validate an automated sample preparation technique for the quantitative evaluation of an expanded cannabinoid
panel (CBD, CBN, THC, THC-A, CBC) in biological matrices, using LC-MS/MS in accordance with the guidelines promulgated by the American Academy of Forensic Sciences Standards Board: Standard Practices for Method Validation in Forensic Toxicology. The inherent limitations of a liquid-liquid extraction will be mitigated by optimizing an automated method using commercially available stationary phase substrates and instrumental conditions to increase selectivity and decrease ionization suppression. This project will allow for DFS and other forensic toxicology
laboratories to adapt to the evolving cannabis industry by expanding cannabinoid testing capabilities. Furthermore, developing an automated process for
sample extraction aims to minimize the potential caseload impacts of decriminalization and/or legalization by increasing laboratory efficiency.
Note: This project contains a research and/or development component, as defined in applicable law, and complies with Part 200 Uniform Requirements - 2 CFR 200.210(a)(14). CA/NCF
- Support NIST Work on Fingerprint Database
- Breath Measurements of Acute Cannabis Use (BACE): Towards Reliable Determination of Recent Use
- The problems with Cannabinoid Analogs (Delta-8 THC, Delta-10 THC and CBD) and their metabolites detectability in urine drug testing for potential cannabinoid abuse.